Paradigm Biocapital Advisors as of June 30, 2026
Portfolio Holdings for Paradigm Biocapital Advisors
Paradigm Biocapital Advisors holds 28 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Revolution Medicines (RVMD) | 22.3 | $1.2B | 6.4M | 187.28 | |
| Nuvalent Inc-a (NUVL) | 13.7 | $732M | 5.9M | 123.50 | |
| Edgewise Therapeutics (EWTX) | 7.8 | $415M | 10M | 40.63 | |
| Genmab A/s Sponsored Ads (GMAB) | 6.8 | $361M | 13M | 27.47 | |
| Spyre Therapeutics Com New (SYRE) | 6.4 | $341M | 3.8M | 88.78 | |
| Apogee Therapeutics (APGE) | 3.9 | $209M | 1.6M | 132.73 | |
| Oruka Therapeutics (ORKA) | 3.8 | $204M | 2.1M | 95.17 | |
| Tango Therapeutics (TNGX) | 3.7 | $199M | 6.4M | 31.26 | |
| Belite Bio Sponsored Ads (BLTE) | 3.6 | $190M | 1.2M | 153.99 | |
| Erasca (ERAS) | 3.3 | $175M | 9.6M | 18.32 | |
| Tarsus Pharmaceuticals (TARS) | 3.3 | $175M | 2.8M | 62.94 | |
| Alnylam Pharmaceuticals (ALNY) | 2.7 | $145M | 480k | 301.03 | |
| Insmed Com Par $.01 (INSM) | 2.6 | $141M | 1.3M | 106.62 | |
| Mbx Biosciences (MBX) | 2.6 | $138M | 2.5M | 55.20 | |
| Vaxcyte (PCVX) | 2.3 | $124M | 2.1M | 58.13 | |
| Miragen Therapeutics (VRDN) | 2.3 | $124M | 6.7M | 18.37 | |
| Olema Pharmaceuticals (OLMA) | 2.0 | $109M | 8.7M | 12.51 | |
| Jade Biosciences Com New (JBIO) | 1.2 | $64M | 2.9M | 22.22 | |
| Tyra Biosciences (TYRA) | 1.1 | $58M | 1.8M | 31.94 | |
| Assembly Biosciences Com New (ASMB) | 0.8 | $43M | 1.6M | 27.48 | |
| Eyepoint Com New (EYPT) | 0.8 | $41M | 2.9M | 14.30 | |
| Achieve Life Sciences (ACHV) | 0.6 | $32M | 5.0M | 6.53 | |
| Vor Biopharma Com New (VOR) | 0.6 | $32M | 1.8M | 18.41 | |
| Maplight Therapeutics (MPLT) | 0.5 | $25M | 686k | 35.84 | |
| Kardigan Ord | 0.4 | $22M | 900k | 23.85 | |
| Lexeo Therapeutics (LXEO) | 0.4 | $19M | 4.2M | 4.66 | |
| Editas Medicine (EDIT) | 0.3 | $18M | 5.6M | 3.24 | |
| Inventiva Sa Ads (IVA) | 0.3 | $15M | 4.0M | 3.78 |
